(NYSE: BIO) Bio Rad Laboratories's forecast annual revenue growth rate of 1.77% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.76%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Bio Rad Laboratories's revenue in 2026 is $2,589,900,000.On average, 6 Wall Street analysts forecast BIO's revenue for 2026 to be $69,526,631,604, with the lowest BIO revenue forecast at $66,395,524,638, and the highest BIO revenue forecast at $73,085,924,138. On average, 6 Wall Street analysts forecast BIO's revenue for 2027 to be $71,185,850,680, with the lowest BIO revenue forecast at $66,395,524,638, and the highest BIO revenue forecast at $76,136,746,310.
In 2028, BIO is forecast to generate $73,112,685,736 in revenue, with the lowest revenue forecast at $67,278,657,372 and the highest revenue forecast at $79,134,045,286.